Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "Hepatology"
DOI: 10.1002/hep.32023
Abstract: Lenvatinib is an effective drug in advanced HCC. Its combination with the anti‐PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is currently being tested in… read more here.
Keywords: death protein; immunomodulatory effects; programmed cell; cell death ... See more keywords
Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology"
DOI: 10.1002/hep.32316
Abstract: Therapeutic blockade of the programmed cell death protein‐1 (PD‐1) immune checkpoint pathways has resulted in significant reactivation of T cell–mediated antitumor immunity and is a promising clinical anticancer treatment modality in several tumor types, but… read more here.
Keywords: cell death; cell; death protein; programmed cell ... See more keywords
Concurrent development of high-stage cutaneous squamous cell carcinoma during complete response of metastatic cutaneous squamous cell carcinoma to programmed cell death protein 1 blockade with cemiplimab
Sign Up to like & getrecommendations! Published in 2021 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2021.10.009
Abstract: cSCC: cutaneous squamous cell carcinoma C utaneous squamous cell carcinoma (cSCC) accounts for over 700,000 cases and an estimated 8000 to 10,000 deaths per year in the United States. Although most cSCCs have an excellent… read more here.
Keywords: death protein; cell carcinoma; squamous cell; cutaneous squamous ... See more keywords
NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Science"
DOI: 10.1111/cas.15243
Abstract: The challenge to improve the clinical efficacy and enlarge the population that benefits from immune checkpoint inhibitors (ICIs) for non‐small‐cell lung cancer (NSCLC) is significant. Based on whole‐exosome sequencing analysis of biopsies from NSCLC patients… read more here.
Keywords: programmed cell; death protein; cell death; ligand therapy ... See more keywords
Corrigendum to “Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer”
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology"
DOI: 10.1155/2019/7921582
Abstract: [This corrects the article DOI: 10.1155/2019/2989048.]. read more here.
Keywords: corrigendum outcomes; death; death protein; programmed cell ... See more keywords
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice
Sign Up to like & getrecommendations! Published in 2018 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/1758835918768238
Abstract: Background: The emergence of novel antiprogrammed cell death protein-1 (PD-1) inhibitors in non-small cell lung cancers (NSCLC) has revolutionized the therapeutic landscape of this disease. Although overall survival (OS) has improved in the first- and… read more here.
Keywords: death protein; cell death; antiprogrammed cell; non small ... See more keywords
Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "World Journal of Clinical Cases"
DOI: 10.12998/wjcc.v11.i7.1458
Abstract: Lymphoma, which is highly malignant, stems from lymph nodes and lymphoid tissue. Lymphoma cells express programmed death-ligand 1/2 (PD-L1/PD-L2), which binds with programmed cell death 1 protein (PD-1) to establish inhibitory signaling that impedes the… read more here.
Keywords: lymphoma; death; immune related; related adverse ... See more keywords
Programmed Cell Death Protein‐1 (PD‐1)‐Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World
Sign Up to like & getrecommendations! Published in 2020 at "OncoTargets and therapy"
DOI: 10.2147/ott.s234868
Abstract: Background Hepatocellular carcinoma (HCC) is one of the most common malignant solid tumors. Its incidence is increasing worldwide due to the dissemination of hepatitis B infection, HCV infection and nonalcoholic steatohepatitis-related HCC. For patients with… read more here.
Keywords: cell death; hepatocellular carcinoma; death protein; carcinoma ... See more keywords
Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Clinical and Molecular Hepatology"
DOI: 10.3350/cmh.2020.0297
Abstract: Corresponding author : Ik Jae Lee Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, Korea Tel: +82-2-2019-3152, Fax: +82-2-2019-4855 E-mail: [email protected] https://orcid.org/0000-0001-7165-3373 Abbreviations: cGAS, cyclic GMP-AMP… read more here.
Keywords: protein; hepatocellular carcinoma; death protein; programmed cell ... See more keywords
A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.788635
Abstract: Lenvatinib has been ratified as a first-line medication for advanced liver tumors by the American Food and Drug Administration. To assess the effectiveness and security of Lenvatinib in the Chinese population in a real-world setting,… read more here.
Keywords: programmed cell; intrahepatic cholangiocarcinoma; hepatocellular carcinoma; death protein ... See more keywords
Real-world experience with anti–programmed cell death protein 1 immunotherapy in patients with esophageal cancer: A retrospective single-center study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.880053
Abstract: The “real-world” data of programmed cell death protein 1 (PD-1) inhibitors in esophageal cancer (EPC) are still an unmet medical need, including the clinical efficacy and safety. Seventy-seven EPC data were studied retrospectively; the progression-free… read more here.
Keywords: cell death; esophageal cancer; death protein; treatment ... See more keywords